{
    "clinical_study": {
        "@rank": "72377", 
        "arm_group": [
            {
                "arm_group_label": "Hexylaminolaevulinate cream", 
                "arm_group_type": "Experimental", 
                "description": "2% hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral)"
            }, 
            {
                "arm_group_label": "Methylaminolaevulinate cream", 
                "arm_group_type": "Active Comparator", 
                "description": "16% methylaminolaevulinate (Metvix, Galderma)"
            }
        ], 
        "brief_summary": {
            "textblock": "This pilot study compares two photosensitizers, hexylaminolaevulinate (HAL) and\n      methylaminolaevulinate (MAL), in treatment of actinic keratoses. Study is conducted using\n      randomized split-face design. Efficacy is assessed clinically, and histologically at 3 and\n      12 months. Pain during and after treatments and adverse reactions at one week are recorded."
        }, 
        "brief_title": "Daylight-mediated Photodynamic Therapy of Actinic Keratoses:Comparing 2%HAL With 16%MAL", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Actinic Keratoses", 
        "condition_browse": {
            "mesh_term": [
                "Keratosis", 
                "Keratosis, Actinic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Study recruites 16-20 voluuntering patients with symmetrical actinic damage on face or\n      scalp. Treatment sites are randomized to receive either hexylaminolaevulinate (HAL) or\n      methylaminolaevulinate (MAL) as photosenstizers (0.25mm-thick layer). Pre-treatment\n      procedures include application of sunscreen for 15 minutes and curettage of the treatment\n      area. Illumination is performed using 2 hours daylight-exposure. Efficacy is assessed\n      clinically, and histologically at 3 and 12 months by blinded observers. Pain during and\n      after treatments and adverse reactions at one week are recorded."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        -Symmetrical actinic damage on face or scalp\n\n        Exclusion Criteria:\n\n          -  Pregnancy\n\n          -  Lactation\n\n          -  Allergy to photosensitizer\n\n          -  Photodermatose"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02149342", 
            "org_study_id": "2013-001389-40"
        }, 
        "intervention": [
            {
                "arm_group_label": "Hexylaminolaevulinate cream", 
                "description": "2% Hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream", 
                "intervention_name": "Hexylaminolaevulinate cream", 
                "intervention_type": "Drug", 
                "other_name": [
                    "HAL", 
                    "Hexvix, Photocure"
                ]
            }, 
            {
                "arm_group_label": "Methylaminolaevulinate cream", 
                "description": "MAL 16% is used as photosensitizer for daylight-PDT", 
                "intervention_name": "Methylaminolaevulinate cream", 
                "intervention_type": "Drug", 
                "other_name": [
                    "16% Methylaminolaevulinate (Metvix, Galderma) cream", 
                    "MAL"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methyl 5-aminolevulinate", 
                "Aminolevulinic Acid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Actinic keratoses", 
            "Daylight-PDT", 
            "Hexylaminolaevulinate", 
            "HAL", 
            "Methylaminolaevulinate", 
            "MAL", 
            "Hyperspectral imaging"
        ], 
        "lastchanged_date": "May 25, 2014", 
        "location": {
            "contact": {
                "email": "noora.neittaanmaki@fimnet.fi", 
                "last_name": "Noora E Neittaanm\u00e4ki-Perttu, MD", 
                "phone": "+358407190362"
            }, 
            "facility": {
                "address": {
                    "city": "Lahti", 
                    "country": "Finland", 
                    "zip": "15850"
                }, 
                "name": "P\u00e4ij\u00e4t-H\u00e4me Central Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Finland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Daylight-mediated Photodynamic Therapy of Actinic Keratoses: a Randomized, Double-blinded Pilot Study Comparing Topical 2% Hexylaminolaevulinate With 16% Methylaminolaevulinate", 
        "overall_contact": {
            "email": "noora.neittaanmaki@fimnet.fi", 
            "last_name": "Noora E Neittaanm\u00e4ki-Perttu, MD", 
            "phone": "+358407190362"
        }, 
        "overall_official": [
            {
                "affiliation": "P\u00e4ij\u00e4t-H\u00e4me Cnetral Hospital, Helsinki University Central Hospital", 
                "last_name": "Noora E Neittaanm\u00e4ki-Perttu, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "P\u00e4ij\u00e4t-H\u00e4me Central Hospital", 
                "last_name": "Mari Gr\u00f6nroos, MD, PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Finland: Finnish Medicines Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Punch biopsies symmetrically on treatment fields prior to treatment and at 3 months, blinded observer (pathologist). HE- and p53-stainings.", 
            "measure": "Histological lesion clearance", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02149342"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Blinded observer", 
                "measure": "Clinical lesion clearance", 
                "safety_issue": "No", 
                "time_frame": "3 months and 12 months"
            }, 
            {
                "description": "Pain is assessed in every 30 minutes during 2-hour sun-exposure and afterwards once in two hours until 9 p.m. (treatment day)", 
                "measure": "Pain assesment (visual analog scale)", 
                "safety_issue": "Yes", 
                "time_frame": "12 hours"
            }, 
            {
                "description": "Blinded observer", 
                "measure": "Adverse reactions", 
                "safety_issue": "Yes", 
                "time_frame": "One week"
            }, 
            {
                "description": "Hyperspectral images prior to treatment and at 3 and 12 months", 
                "measure": "Clerance of field cancerization in hyperspectral images", 
                "safety_issue": "No", 
                "time_frame": "3 and 12 months"
            }
        ], 
        "source": "Joint Authority for P\u00e4ij\u00e4t-H\u00e4me Social and Health Care", 
        "sponsors": {
            "collaborator": {
                "agency": "Helsinki University Central Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Joint Authority for P\u00e4ij\u00e4t-H\u00e4me Social and Health Care", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}